Bowling Portfolio Management LLC Increases Holdings in Sucampo Pharmaceuticals, Inc. (SCMP)

Bowling Portfolio Management LLC lifted its stake in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 37.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 166,088 shares of the biopharmaceutical company’s stock after purchasing an additional 45,035 shares during the period. Bowling Portfolio Management LLC owned 0.35% of Sucampo Pharmaceuticals worth $2,981,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Schwab Charles Investment Management Inc. grew its holdings in Sucampo Pharmaceuticals by 36.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 246,796 shares of the biopharmaceutical company’s stock valued at $2,592,000 after buying an additional 66,493 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Sucampo Pharmaceuticals by 0.9% during the 2nd quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 423 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Sucampo Pharmaceuticals by 5.6% during the 2nd quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock worth $126,000 after purchasing an additional 631 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Sucampo Pharmaceuticals by 9.0% during the 2nd quarter. Legal & General Group Plc now owns 44,756 shares of the biopharmaceutical company’s stock worth $470,000 after purchasing an additional 3,701 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of Sucampo Pharmaceuticals by 1.4% during the 2nd quarter. Principal Financial Group Inc. now owns 190,845 shares of the biopharmaceutical company’s stock worth $2,004,000 after purchasing an additional 2,712 shares in the last quarter. Institutional investors and hedge funds own 67.09% of the company’s stock.

In related news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the sale, the insider now owns 52,023 shares of the company’s stock, valued at $858,379.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.13% of the company’s stock.

SCMP has been the topic of several analyst reports. Zacks Investment Research raised Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Tuesday, October 17th. Mizuho restated a “hold” rating and set a $12.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Wednesday, November 1st. Maxim Group restated a “buy” rating and set a $23.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Thursday, November 2nd. B. Riley began coverage on Sucampo Pharmaceuticals in a research report on Tuesday, November 14th. They set a “buy” rating and a $14.00 price objective for the company. Finally, started coverage on Sucampo Pharmaceuticals in a research report on Wednesday, November 15th. They set a “buy” rating and a $14.00 price objective for the company. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Sucampo Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $20.25.

Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) remained flat at $$18.00 on Wednesday. Sucampo Pharmaceuticals, Inc. has a 1 year low of $9.30 and a 1 year high of $18.75. The stock has a market cap of $849.02, a PE ratio of -5.47, a P/E/G ratio of 5.06 and a beta of 1.38. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37.

COPYRIGHT VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/14/bowling-portfolio-management-llc-grows-holdings-in-sucampo-pharmaceuticals-inc-scmp.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply